Peptides displayed by HLA for use in immunotherapy against different types of cancers
AssigneeImmatics Biotechnologies GmbH
InventorsRicarda Hannen, Jens Hukelmann, Florian Koehler, Daniel Johannes Kowalewski, Heiko Schuster, Oliver Schoor, Michael Roemer, Chih-Chiang Tsou, Jens Fritsche
Life of this patent
Estimating the term…
Abstract
The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
Claims27
A peptide consisting of the amino acid sequence VFLLLPYPRF (SEQ ID NO:
- 31) in the form of a salt.
A peptide consisting of the amino acid sequence VFLLLPYPRF (SEQ ID NO:
- 31) in the form of a pharmaceutically acceptable salt.
A pegylated peptide consisting of the amino acid sequence of VFLLLPYPRF (SEQ ID NO:
- 31) or a pharmaceutically acceptable salt thereof modified with PEG.
Dependencies are inferred from the claim text.